Benefits
Wound Healing and Scar Improvement
TECA (Total Triterpenic Fraction of Centella Asiatica) has well-established wound healing effects. Multiple trials show topical application improves wound healing, reduces scar formation, treats keloids and hypertrophic scars. Arpaia 1990 and others established this as foundational application.
Chronic Venous Insufficiency
Multiple European trials show gotu kola extract (TECA, Centellase®) improves CVI symptoms — leg heaviness, edema, capillary fragility. Pointel 1987 and trials established efficacy. Mechanism: collagen synthesis support, microcirculation improvement.
Anxiety and Cognitive Support
trial showed gotu kola attenuated startle response in anxiety disorders. trial showed cognitive improvements in elderly. Modest evidence for anxiolytic and cognitive effects; mechanism includes GABA modulation.
Burn Treatment / Skin Healing
Topical and oral TECA used for burn treatment, post-surgical healing. Reduces inflammation, supports tissue regeneration. Component of medical-grade scar treatment products.
Stretch Mark Prevention/Treatment
Centella-containing creams used during pregnancy and postpartum for stretch mark prevention. trial showed reduced stretch mark development with topical application. Modest but consistent evidence.
Mechanism of action
Collagen Synthesis Stimulation
Triterpenes (especially asiaticoside, madecassoside) stimulate fibroblast proliferation and collagen type I and III synthesis. Foundational mechanism for wound healing, scar improvement, and connective tissue applications.
Microcirculation Enhancement
Improves capillary integrity and microcirculation — basis for venous insufficiency and capillary fragility applications.
GABA Modulation (Anxiolytic)
Some triterpenes modulate GABA-A receptors — basis for anxiolytic effects. Modest activity.
Neurotrophic Effects (BDNF)
Animal studies show centella increases BDNF and neurogenesis — basis for cognitive applications. Mechanism for theoretical anti-aging brain effects.
Antioxidant / Anti-Inflammatory
Direct antioxidant activity plus anti-inflammatory effects via NF-κB modulation. Contributes to multiple applications.
Clinical trials
Multiple European RCTs of TECA (60-120 mg/day) for chronic venous insufficiency.
CVI patients across multiple trials.
Significant improvements in symptoms (leg heaviness, edema, pain) and microcirculation parameters. Established TECA as evidence-based CVI treatment in European phytomedicine.
Single-dose RCT of gotu kola (12 g dried plant) vs placebo on acoustic startle response in healthy subjects.
40 healthy subjects.
Significantly attenuated startle response (anxiolytic biomarker) vs placebo. Suggested anxiolytic effects without sedation. Single-dose; limited generalizability.